If I have to vote for one of the strangest market reactions to a quarterly report, GoPro’s (GPRO) recent Q3’17 numbers are probably on the top of my list.
First of all, GPRO’s management had guided higher two months earlier, stating revenue will be in the upper range between $290M and $310M. Not only did it beat that number (which was already something the market did not expect), but it beat it by a whopping $20M and the revenue increase was 37% Y/Y.
If that was not enough, the company reported GAAP EPS of $0.10 and adjusted EPS of $0.15, blowing the consensus by $0.13.
And the end result was that the stock was down by about 11% on the reporting date. Supposedly, the reason for the drop was guidance that called for about $470M in revenue for Q4 vs. the $520M the market was expecting.
So is the market right or wrong? The market is dead wrong, of course, it just doesn’t know it yet. To give you just one reason why the market is wrong, please take a look at the chart below:
stock market performance: Mallinckrodt plc(MNK)
- [By Ben Levisohn]
Mallinckrodt (MNK) tumbled to the bottom of the S&P 500 today after Citron Research accused the company of fraud.
Mallinckrodt tumbled 12% to $59.60 today, while the S&P 500 declined 0.2% to 2,176.94.
Leerink’s Jason Gerberry and Etzer Darout explain the allegations:
Mallinckrodtshares are down -7-8% based on a short report citing CMS dashboard data which call into question Acthar Gel sales derived from government sources (CMS; Medicaid & Medicare). The report appears to overstate Acthar CMS sales as a percent of total product sales, as the methodology utilized by CMS drug spending dashboard for Medicare spend is based on gross sales, not net., although it’s unclear to what extent Acthar CMS sales are overstated.
The report suggestsMallinckrodt mgmt understated combined Medicaid/Medicare sales on an investor call, saying it was about a little bit higher than a quarter of the business vs. gross sales on CMS dashboard implying sales were 61% of total Acthar net revenue (an apples to oranges comparison). We dont know the exact net sales of Acthar to Medicare/Medicaid, but we believe it is safe to assume Medicaid, after CPI price penalties had high discounts/rebates and assuming an 80% gross-to-net ratio on the Medicare book ($504m gross) suggests Acthar net sales would be closer to 38-45% range vs. the 61% figure cited in the short-report. Why this may matter Acthar Gel is an old product lacking good randomized, controlled data consistent with most products approved in the modern era. The report appears to be an attempt to call into question whether the government should be paying Acthars average $80-100k net price/patient/year by calling to this to the attention of government figures who have been targeting excessive drug pricing issues. This type of issue became a major headache for Mylan (MYL) investors recently with EpiPen.Mallinckrodt is presenting at a compe
- [By Keith Speights]
That’s the question investors are trying to answer about how President Trump’s policies might impact healthcare stocks. So far, specific policy proposals put forward by the president appear likely to cause significant problems for certain healthcare stocks. Here’s why three of President Trump’s policies could be downright terrible for Molina Healthcare(NYSE:MOH), Mallinckrodt (NYSE:MNK), and Illumina (NASDAQ:ILMN).
- [By Ben Levisohn]
Mallinckrodt (MNK) tumbled to the bottom of the S&P 500 today after its earnings topped the Street consensus but offered commentary that spooked investors.
Agence France-Presse/Getty Images
Shares of Mallinckrodt dropped 9.1% to $52.42, while the S&P 500 rose 0.1%.
Barclays analyst Douglas Tsao and Morgan Williams callMallinckrodt’s plunge “outsized.” They explain why:
In our view the sell-off afterMallinckrodt reported CY3Q16 earnings is outsized considering much of the disclosure on the call was largely expected, including specialty generics weakness and the 2017 outlook, which seemed relatively mild. While outsized Acthar contribution to EBITDA may be accounting for some of the sell-off, wed argue that there is benefit to the brand outperforming, especially considering the need to offset Therakos production issues in CY4Q16 and CY1Q17 as well as specialty generics weakness. We recognize some lingering headline risk associated with media reports criticizing the cost of Acthar to Medicare, after CMS released its prescription drug spending dashboard.
Mallinckrodt’s market capitalization fell to $5.7 billion today from $6.2 billion yesterday. It reported net income of $306 million on revenue of $3.3 billion in 2015.
This marks the third time in less than two weeks that Mallinckrodt was the S&P 500′s biggest loser.
- [By Johanna Bennett]
Sell-side analysts continue to defend drug maker Mallinckrodts (MNK) shares on the heel of Citron Researchs report on the company released last week.
Earlier today, UBS analyst Marc Goodman and his team weighed into the fray, proclaiming that a misunderstood situation creates opportunity.
Goodman, who rates Mallinckrodt at a buy with a $92 price target, argues that Mallinckrodt is a different breed from other specialty drug makers, with high-quality earnings, sales growth fueled by volume not price hikes and an emerging pipeline we think is not just underappreciated but really not even part of the conversation with most investors.
Also, he argues that Mallinckrodt continues to be misunderstood by investors.
Goodman goes into goes into more detail:
we were surprised this past week by the debate around Acthar’s Medicare exposure (~30% or ~40%), which in our view has little relevance to the overall MNK story. The key debate since the Questcor deal has been Acthar payer coverage and concerns for more barriers andor coverage blocks by the payers. There was reason for concern just 2 years ago, in our view, as several important payers increased barriers. But mgt’s aggressive focus on enhancing clinical and health-economics data to help support better coverage seems to be working and has resulted in improved coverage, which we believe is still not well appreciated.
Mallinckrodt shares continue to climb today, rising 4.8% to a recent $57.20.
stock market performance: WashingtonFirst Bankshares Inc(WFBI)
- [By WWW.GURUFOCUS.COM]
For the details of CASTLE CREEK CAPITAL PARTNERS IV, LP’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=CASTLE+CREEK+CAPITAL+PARTNERS+IV%2C+LP
These are the top 5 holdings of CASTLE CREEK CAPITAL PARTNERS IV, LPGuaranty Bancorp (GBNK) – 1,448,849 shares, 39.1% of the total portfolio. MBT Financial Corp (MBTF) – 1,876,423 shares, 23.6% of the total portfolio. WashingtonFirst Bankshares Inc (WFBI) – 489,377 shares, 15.19% of the total portfolio. Shares added by 4558.07%Eastern Virginia Bankshares Inc (EVBS) – 1,061,225 shares, 12.33% of the total portfolio. First NBC Bank Holding Co (FNBC) – 2,205,382 shares, 9.78% of the total portfolio. Added: Wa
stock market performance: Monotype Imaging Holdings Inc.(TYPE)
- [By Lisa Levin]
Shares of Monotype Imaging Holdings Inc. (NASDAQ: TYPE) were down around 12 percent to $20.90 after the company posted downbeat quarterly earnings.
- [By Lisa Levin]
Wednesday afternoon, the non-cyclical consumer goods & services shares surged 0.61 percent. Meanwhile, top gainers in the sector included Monotype Imaging Holdings Inc. (NASDAQ: TYPE), up 9 percent, and Semiconductor Manufacturing Int'l (ADR) (NYSE: SMI), up 6 percent.
stock market performance: CGG(CGG)
- [By Jonas Elmerraji]
First up is French oil service firm CGG Veritas (CGG)
. The Eurozone-based energy stock hasn’t exactly posted blockbuster performance in 2013, but investors who ignore CGG for the final stretch of the year could be making a big mistake. That’s because of a bullish technical pattern that’s emerging in shares right now.
CGG spent most of the last eight months looking anything but bullish. But an ascending triangle pattern is changing that. The pattern is formed by horizontal resistance to the upside at $26, and uptrending support to the below shares. Basically, as CGG bounces in between those two technical levels, it’s getting squeezed closer and closer to a breakout above $26. When that happens, traders have a buy signal.
The ascending triangle pattern in CGG Veritas isn’t exactly textbook. That’s because the setup is forming at the bottom of a downtrend, rather than in the middle of an uptrend – but it’s a mistake to get caught up on the textbook pictures of what trading patterns are supposed to look like. On a move through $26, the trading implications are just as actionable.
- [By Lisa Levin]
CGG SA (ADR) (NYSE: CGG) shares shot up 32 percent to $7.15 after the company reported an agreement in principle on financial restructuring plan with main creditors and DNCA.
- [By Lisa Levin]
Friday afternoon, the energy sector proved to be a source of strength for the market. Leading the sector was strength from CGG SA (ADR) (NYSE: CGG) and Geospace Technologies Corporation (NASDAQ: GEOS).
stock market performance: Alphatec Holdings, Inc.(ATEC)
- [By Lisa Levin]
Shares of Alphatec Holdings Inc (NASDAQ: ATEC) were down around 25 percent to $2.00 as the company reported an $18.9 million private placement.
Heat Biologics Inc (NASDAQ: HTBX) was down, falling around 15 percent to $0.872. Heat Biologics priced its 5 million share offering at $0.80 per share.
- [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha)
Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha)
Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period.
Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share.
Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement.
Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share.
Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76.
QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share.
Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering.
Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston